ENUMOTCinactive

ENUMERAL BIOMEDICAL HOLDINGS, INC.

Healthcare·Oncology·Pre-clinical
Oncology

ENUMERAL BIOMEDICAL HOLDINGS, INC. (ENUM): 5 pipeline candidates · ~1 mo cash runway. Updated within the last hour.

5.2/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.4

1.4 months

Financial Health10.0

D/E -1.46 · 0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ENUMERAL BIOMEDICAL HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$209K

Quarterly Burn

$645K

Runway

1.4 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (5 candidates)

DrugPhase
244c8Preclinical
388d4Preclinical
enum005Preclinical
enum008Preclinical
enum009Preclinical

Frequently asked questions

How many drug candidates are in ENUMERAL BIOMEDICAL HOLDINGS, INC.'s pipeline?

ENUMERAL BIOMEDICAL HOLDINGS, INC. (ENUM) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is ENUMERAL BIOMEDICAL HOLDINGS, INC.'s lead drug candidate?

ENUMERAL BIOMEDICAL HOLDINGS, INC.'s most advanced tracked candidate is 244c8 (Preclinical) for Solid tumors.

What is ENUMERAL BIOMEDICAL HOLDINGS, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, ENUMERAL BIOMEDICAL HOLDINGS, INC. has approximately 1.4 months of cash runway.

Get the full picture on ENUMERAL BIOMEDICAL HOLDINGS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar